Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours

被引:0
|
作者
A R Marques
C Espadinha
M J Frias
L Roque
A L Catarino
L G Sobrinho
V Leite
机构
[1] Centro de Investigação de Patobiologia Molecular,
[2] Instituto Português de Oncologia Francisco Gentil,undefined
[3] Rua Professor Lima Basto,undefined
[4] Departamento de Patologia Morfológica,undefined
[5] Instituto Português de Oncologia Francisco Gentil,undefined
[6] Rua Professor Lima Basto,undefined
来源
British Journal of Cancer | 2004年 / 91卷
关键词
PPAR; PAX8; underexpression; follicular thyroid tumours;
D O I
暂无
中图分类号
学科分类号
摘要
The expression of peroxisome proliferator-activated receptor (PPAR)γ in thyroid neoplasias and in normal thyroid (NT) tissues has not been fully investigated. The objectives of the present work were: to study and compare the relative expression of PPARγ in normal, benign and malignant thyroid tissues and to correlate PPARγ immunostaining with clinical/pathological features of patients with thyroid cancer. We analysed the expression of PPARγ in several types of thyroid tissues by reverse transcription–polymerase chain reaction (RT–PCR), interphase fluorescent in situ hybridisation, real-time RT–PCR and immunohistochemistry. We have demonstrated that NT tissues express PPARγ both at mRNA and at protein level. PAX8-PPARγ fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs). By real-time RT–PCR, we observed that tumours negative for the PAX8-PPARγ rearrangement expressed lower levels of PPARγ mRNA than the NT. Overexpression of PPARγ transcripts was detected in 80% (four of five) of translocation-positive tumours. Diffuse nuclear staining was significantly (P<0.05) less prevalent in FTCs (53%; 18 of 34), PTCs (49%; 19 of 39) and PDTCs (0%; zero of 13) than in normal tissue (77%; 36 of 47). Peroxisome proliferator-activated receptorγ-negative FTCs were more likely to be locally invasive, to persist after surgery, to metastasise and to have poorly differentiated areas. Papillary thyroid carcinomas with a predominantly follicular pattern were more often PPARγ negative than classic PTCs (80% vs 28%; P=0.01). Our results demonstrated that PPARγ is underexpressed in translocation-negative thyroid tumours of follicular origin and that a further reduction of PPARγ expression is associated with dedifferentiation at later stages of tumour development and progression.
引用
收藏
页码:732 / 738
页数:6
相关论文
共 50 条
  • [41] Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: Promising new therapeutic targets?
    Sertznig, Pit
    Seifert, Markus
    Tilgen, Wolfgang
    Reichrath, Joerg
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) : 383 - 386
  • [42] Peroxisome proliferator-activated receptor β/δ goes vascular
    Bishop-Bailey, David
    CIRCULATION RESEARCH, 2008, 102 (02) : 146 - 147
  • [43] Peroxisome proliferator-activated receptor ligands in atherosclerosis
    Viles-Gonzalez, JF
    Choi, BG
    Fuster, V
    Badimon, JJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1393 - 1403
  • [44] Stabilization of peroxisome proliferator-activated receptor α by the ligand
    Hirotani, M
    Tsukamoto, T
    Bourdeaux, J
    Sadano, H
    Osumi, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (01) : 106 - 110
  • [45] Regulatory role of peroxisome proliferator-activated receptor delta (PPARδ) in muscle metabolism.: A new target for metabolic syndrome treatment?
    Grimaldi, PA
    BIOCHIMIE, 2005, 87 (01) : 5 - 8
  • [46] Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells:: Thiazolidinediones are partial PPARγ agonists
    Chana, RS
    Lewington, AJ
    Brunskill, NJ
    KIDNEY INTERNATIONAL, 2004, 65 (06) : 2081 - 2090
  • [47] Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists
    Kajita, Daisuke
    Nakamura, Masaharu
    Matsumoto, Yotaro
    Ishikawa, Minoru
    Hashimoto, Yuichi
    Fujii, Shinya
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (16) : 3350 - 3354
  • [48] Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists
    Okazaki, Shogo
    Shioi, Ryuta
    Noguchi-Yachide, Tomomi
    Ishikawa, Minoru
    Makishima, Makoto
    Hashimoto, Yuichi
    Yamaguchi, Takao
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (21) : 5455 - 5461
  • [49] Carbacyclin induces carnitine palmitoyltransferase-1 in cardiornyocytes via peroxisome proliferator-activated receptor (PPAR) δ independent of the IP receptor signaling pathway
    Kuroda, Tadashi
    Hirota, Hisao
    Fujio, Yasushi
    Suglyama, Shoko
    Masaki, Mitsuru
    Hiramoto, Yoshimune
    Shioyama, Wataru
    Okamoto, Kitaro
    Horl, Masatsugu
    Yamauchi-Takihara, Keiko
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2007, 43 (01) : 54 - 62
  • [50] Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism.: A new target for the treatment of metabolic syndrome
    Luquet, S
    Lopez-Soriano, J
    Holst, D
    Gaudel, C
    Jehl-Pietri, C
    Fredenrich, A
    Grimaldi, PA
    BIOCHIMIE, 2004, 86 (11) : 833 - 837